New Drug Combination Shows Promise for Rapid Relief From Suicidal Thoughts

A more effective suicidal thoughts treatment may be on the horizon, according to new research that points to an unexpected pairing of drugs. The study suggests that a single ketamine infusion followed by low-dose buprenorphine can produce meaningful and sustained reductions in suicidal ideation, addressing one of psychiatry’s most stubborn challenges.

The Problem This Research Aims to Solve

Modern psychiatry has long faced a painful limitation: the people at greatest risk of suicide often cannot afford to wait weeks for traditional antidepressants or therapy to take effect.

The scale of the crisis underscores why faster options matter so much. Each year, roughly 13 million Americans seriously consider suicide, and about 50,000 die by suicide annually. A treatment capable of working quickly, rather than over the course of weeks, could fill a critical and dangerous gap in care.

What the Study Found

The new research, set to be presented at the American Psychiatric Association’s annual meeting, tested a surprising drug combination in adults with major depressive disorder and active suicidal behavior.

The trial was a randomized, double-blind, placebo-controlled study, the gold standard for clinical research, and it worked as follows:

• It involved 50 patients with major depression and active suicidal behavior.
• All participants first received a single IV infusion of ketamine.
• Two days later, they were randomly assigned to receive either an ultra-low dose of buprenorphine or a placebo for four weeks.
• Patients were assessed weekly throughout the study.

The key result was that the ketamine-and-buprenorphine regimen significantly sustained reductions in suicidal thoughts over the treatment period.

Ned Kalin, chair of the Department of Psychiatry at the University of Wisconsin School of Medicine and Public Health and editor-in-chief of the journal publishing the paper, described it as a genuine breakthrough study, one that offers both hope and immediate clinical applications.

Why These Two Drugs?

The pairing may sound unusual, since both drugs are better known for other uses.

Ketamine is an anesthetic long used in hospitals for sedation and pain relief, though it is also recognized in popular culture as a party drug. More recently, it has emerged as an off-label treatment for depression, PTSD, and suicidal thoughts. Its use has largely been confined to emergency situations, partly because its effects often fade within days or weeks and because it can carry serious side effects.

Buprenorphine, meanwhile, is best known as a medication for treating opioid addiction during the overdose crisis, and it is sometimes prescribed for pain as well.

The rationale for combining them grew out of earlier research suggesting a close connection between physical pain, psychological pain, and suicidality. Study authors Alan F. Schatzberg and Jason M. Tucciarone of Stanford University School of Medicine pointed to a 2016 Israeli study that helped inspire the approach.

A Curious Finding About Depression

One of the study’s more puzzling results involved depression itself.

According to Tucciarone, both the placebo group and the ketamine-plus-buprenorphine group experienced reductions in depressive symptoms, which researchers had expected given ketamine’s known antidepressant effects. However, there was no statistically significant difference between the two groups when it came to depression specifically.

Tucciarone called this outcome both peculiar and interesting, adding that it represents an ongoing area that requires further study. In other words, the drug combination’s clearest benefit appeared to be on suicidal thoughts rather than on depression as a whole.

After treatment ended, researchers observed some rebound in both depressive symptoms and suicidal thoughts, though patients still remained improved compared with their baseline before treatment. Notably, no signs of withdrawal symptoms were observed.

Experts Urge Caution

Despite the encouraging results, researchers not involved in the study stressed that important questions remain unanswered.

Bertha Madras, a professor of psychobiology at Harvard Medical School, called the findings intriguing but warned against moving too quickly. She noted that promising treatments often look beneficial in the short term, and that adverse consequences may only emerge once a therapy is used in larger populations over longer periods.

Carl Hart, a professor of psychology at Columbia University, similarly cautioned against overstating the results. He pointed out that while the study showed improvement in suicidal thoughts, it did not demonstrate a difference in depressive symptoms between the two groups, and that its conclusions were based on questionnaires rather than real-world outcomes. He described the result as a promising signal, but emphasized the need to follow it up in people genuinely contemplating suicide to see how well it performs.

The Bottom Line

This study points to a potentially scalable and safe new option for people at risk of suicide, which the researchers believe could be clinically meaningful. The combination of a single ketamine infusion followed by low-dose buprenorphine offers a rare prospect of rapid relief in a field where speed can be lifesaving.

Still, the findings are an early signal rather than a finished answer. With a small group of 50 patients, outcomes measured through questionnaires, and an unexplained lack of effect on depression itself, longer and larger studies will be needed before this approach can be widely adopted. For now, it represents a hopeful step in an area of medicine that urgently needs one.

If you or someone you know needs help, support is available. You can visit 988lifeline.org or call or text the Suicide and Crisis Lifeline at 988.